Carillizumab is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. All registered phases are Phase 2. The lead sponsor is Second Affiliated Hospital, Zhejiang University, School of Medicine. The most-studied condition is Esophageal Squamous Cell Carcinoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
NCT06576973 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Neoadjuvant Treatment
|
Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | China |
|
Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
NCT04666090 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
|
Phase 2 | Active, closed | Second Affiliated Hospital, Zhejiang University, School of Medicine | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Carillizumab as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Second Affiliated Hospital, Zhejiang University, School of Medicine. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Carillizumab works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Carillizumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Carillizumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.